Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 3Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 55Multiple Myeloma 53Hodgkin Disease 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, Non-Hodgkin 46Leukemia, Lymphocytic, Chronic, B-Cell 44Myelodysplastic Syndromes 41Lymphoma, Mantle-Cell 39Lymphoma, Large B-Cell, Diffuse 38Lymphoma, Follicular 36Leukemia 36Congenital Abnormalities 36Burkitt Lymphoma 34Myeloproliferative Disorders 31Lymphoma 30Lymphoma, B-Cell, Marginal Zone 29Lymphoma, Large-Cell, Immunoblastic 28Leukemia, Myeloid, Accelerated Phase 27Leukemia, Myeloid, Chronic-Phase 26Waldenstrom Macroglobulinemia 25Blast Crisis 25Leukemia, Myelomonocytic, Chronic 24Recurrence 19Primary Myelofibrosis 19Lymphoma, T-Cell, Cutaneous 19Neoplasms, Plasma Cell 18Lymphoma, Large-Cell, Anaplastic 18Myelodysplastic-Myeloproliferative Diseases 16Sezary Syndrome 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15

Interventions

Melphalan 5fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Cyclophosphamide 3Tacrolimus 2pomalidomide 1ixazomib 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1auricularum 1Stem Cell Transplantation 1Sirolimus 1Panobinostat 1Lenalidomide 1High-Throughput Screening Assays 1Gemcitabine 1Filgrastim 1Etoposide 1Dexamethasone 1Cytarabine 1Carmustine 1Calcium Dobesilate 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Leukemia, Plasma Cell × Peripheral Blood Stem Cell Transplantation × Clear all
NCT02506959 2025-03-18

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

NCT01008462 2019-06-11

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Center

Phase 2 Completed
16 enrolled 15 charts
LymphoidOther hematologic neoplasmPlasma cell

Chromosome 17 deletion, Hodgkin Disease, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, B-Cell

NCT00307086 2017-03-06

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
30 enrolled 7 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡